Q3 2025 Roivant Sciences Ltd Earnings Call Transcript
Key Points
- Roivant Sciences Ltd (ROIV) reported positive phase 2 results for Brepo in cutaneous sarcoidosis, showing a significant placebo-adjusted improvement of 21.6 points.
- The company has fully enrolled its phase 2b study for 1,402 in DCRA and phase 2 study for Mosley in PHLD, indicating strong progress in its pipeline.
- Roivant Sciences Ltd (ROIV) has a robust pipeline with multiple registrational programs, including three indications for Brepo, showcasing its potential as a 'pipeline in a product'.
- The company maintains a strong financial position with $4.5 billion in consolidated cash, providing ample capital to reach profitability and pursue additional opportunities.
- Roivant Sciences Ltd (ROIV) is on track for multiple pivotal study readouts and potential commercial launches, including the NDA for Brepo in dermatomyositis, highlighting a catalyst-rich period ahead.
- The phase 2 study for Brepo in cutaneous sarcoidosis was not powered for efficacy, which may raise questions about the robustness of the results.
- There are imbalances in the baseline characteristics of the study arms, which could impact the interpretation of the efficacy data.
- The company faces ongoing litigation with Moderna, which could pose legal and financial risks.
- Roivant Sciences Ltd (ROIV) has not yet finalized the pricing strategy for Brepo, creating uncertainty around its commercial potential.
- The competitive landscape for Brepo and other pipeline products remains challenging, with potential competition from other JAK inhibitors and emerging therapies.
Good day and thank you for standing by. Welcome to the Roivant thirdquarter 2025 earnings conference call. (Operator Instructions) Please be advised that today's conference is being recorded. I would now like to hand the conference over to your speaker today, Stephanie Lee. Please go ahead.
Good morning and thanks for joining today's call to review positive phase 2 results for breakfast fitness and cutaneous sarcoidosis, and Roman's financial results for the 3rd quarter ended December 31, 2025. And Stephanie Lee with Rogan, presenting today, we have Mattines, CEO of Regan, and Ben Zimmer, CEO of Privan. For those dialing in via conference call, you can find the slides being presented today as well as the press release announcing these updates on our IR website at www.investor.roant.com.
We'll also be providing the current flight numbers as we present to help You follow them up. I would like to remind you that we'll be
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
Trustpilot
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
